期刊文献+

抗HIV药物硫酸阿扎那韦关键中间体的合成工艺研究 被引量:1

Synthesis of Key Intermediate of Anti-HIV Drug Atazanavir Sulfate
下载PDF
导出
摘要 以L-苯丙氨酸(3)为原料,经Boc保护、酰氯化、取代、脱羧、氯代,"一锅"制得(S)-4-苯基-3-(叔丁氧羰基)氨基-1-氯-2-丁酮(6),优化条件下收率达70.4%。6经还原和环合得到(2R,3S)-4-苯基-1,2-环氧-3-叔丁氧羰基氨基丁烷(1)。对影响收率的碱的种类、反应温度、还原剂等因素进行了工艺优化,优化条件下收率85.7%,产品纯度99%。1及中间体的结构经^(1)H NMR、^(13)C NMR和ESI-MS确证。该工艺方法操作简单,原料价廉、收率高。 L-Phenyl-alamine was Boc-protected to afford N-Boc-L-phenyl-alamine after using an one-pot method including acylating chlorination,substitution,decarboxylation and chlorination.(S)-4-Phenyl-3-(N-Bocamino)-1-chloro-2-butanone 6 was obtained with a yield of 70.4%.Then (2R,3S)-4-phenyl-3-(N-Boc-amino)-1-oxirane-butane 1 was synthesized from compound ■ through reduction and cyclization with a yield of of 85.7%and a chromatographic purity of 99%.The affecting factors including the reaction temperature,the kinds of the base and the reductant were studied.The structures of the compound 1 and intermediates were characterized by1H NMR,13C NMR and ESI-MS.The preparation process was simple in operation,low in raw material cost,high yield.
作者 刘志 仲金璐 陈成 李响 程青芳 LIU Zhi;ZHONG Jin-lu;CHEN Cheng;LI Xiang;CHENG Qing-fang(Lianyungang Guike Pharmaceutical Co.,Ltd.,Lianyungang 222000,China;School of Pharmacy,Jiangsu Ocean University,Lianyungang 222005,China)
出处 《精细化工中间体》 CAS 2020年第6期45-48,60,共5页 Fine Chemical Intermediates
基金 连云港高新区科技计划项目(ZD201917)。
关键词 硫酸阿扎那韦 中间体 还原 环合 atazanavir sulfate intermediate reduction cyclization
  • 相关文献

参考文献4

二级参考文献33

  • 1Goldberg A L. Protein degradation and protection against misfolded or damaged proteins[J].Nature,2003.895-899. 被引量:1
  • 2Adams J. The proteasome:a suitable antineoplastic target[J].Nature Reviews Cancer,2004.349-360. 被引量:1
  • 3Goldberg A L. Functions of the proteasome:from protein degradation and immune surveillance to cancer therapy[J].Biochemical Society Transactions,2007.12-17. 被引量:1
  • 4Orlowski R Z,Zeger E L. Targeting the proteasome as a therapeutic strategy against haematological malignancies[J].Expert Opinion on Investigational Drugs,2006.117-130. 被引量:1
  • 5Orlowski R Z,Kuhn D J,Lessons from the first decade. Proteasome inhibitors in cancer therapy[J].Clinical Cancer Research,2008.1649-1657. 被引量:1
  • 6Whitby F G,Masters E I,Kramer L. Structural basis for the activation of 20S proteasomes by 11S regulators[J].Nature,2000,(6808):115-120. 被引量:1
  • 7Zavrski I,KleebergL,Kaiser M. Proteasome as an emerging therapeutic target in cancer[J].Current Pharmaceutical Design,2007.471-485. 被引量:1
  • 8Meiners S,Ludwig A,Stangl V. Proteasome inhibitors:Poisons and remedies[J].Medicinal Research Reviews,2008.309-327. 被引量:1
  • 9Borissenko L,Groll M. 20S proteasome and its inhibitors:Crystallographic knowledge for drug development[J].Chemical Reviews,2007.687-717. 被引量:1
  • 10Vinitsky A,Michaud C,Powers J C. Inhibition of the chymotrypsi N-like activity of the pituitary multicatalytic proteinase complex[J].Biochemistry,1992.9421-9428. 被引量:1

共引文献3

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部